This Molecular Cancer Therapeutics collection features a selection of recently published research and review articles that explore the development of novel antibody-drug conjugates or their mechanisms of resistance. MCT welcomes the submissions of impactful research articles, reviews, and commentaries in this and other related categories.
Mechanisms of Resistance to Antibody-Drug Conjugates
Loganzo F…Gerber HP. Molecular Cancer Therapeutics 2016.
A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity
Miller ML…Chari RVJ. Molecular Cancer Therapeutics 2016.
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Black J…Santin AD. Molecular Cancer Therapeutics 2016.
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Chang CH…Goldenberg DM. Molecular Cancer Therapeutics 2016.
LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong X…Carmon KS. Molecular Cancer Therapeutics 2016.
Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis
Currier NV…Cochran JR. Molecular Cancer Therapeutics 2016.
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
Singh R…Widdison WC. Molecular Cancer Therapeutics 2016.
Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker
Morrison K…Stover DR. Molecular Cancer Therapeutics 2016.
Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates
Burke PJ…Jeffrey SC. Molecular Cancer Therapeutics 2016.
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Dorywalska M…Strop P. Molecular Cancer Therapeutics 2016.
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Phillips AC…Reilly EB. Molecular Cancer Therapeutics 2016.
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Weekes CD…Colon-Otero G. Molecular Cancer Therapeutics 2016.
Molecular Cancer Therapeutics Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (267) 765-1090 | E-mail: [email protected]